PMID- 11306230
OWN - NLM
STAT- MEDLINE
DCOM- 20011207
LR  - 20220309
IS  - 0749-3797 (Print)
IS  - 0749-3797 (Linking)
VI  - 20
IP  - 3 Suppl
DP  - 2001 Apr
TI  - The art and science of incorporating cost effectiveness into evidence-based 
      recommendations for clinical preventive services.
PG  - 36-43
AB  - As medical technology continues to expand and the cost of using all effective 
      clinical services exceeds available resources, decisions about health care 
      delivery may increasingly rely on assessing the cost-effectiveness of medical 
      services. Cost-effectiveness is particularly relevant for decisions about how to 
      implement preventive services, because these decisions typically represent major 
      investments in the future health of large populations. As such, decisions 
      regarding the implementation of preventive services frequently involve, 
      implicitly if not explicitly, consideration of costs. Cost-effectiveness analysis 
      summarizes the expected benefits, harms, and costs of alternative strategies to 
      improve health and has become an important tool for explicitly incorporating 
      economic considerations into clinical decision making. Acknowledging the 
      usefulness of this tool, the third U.S. Preventive Services Task Force (USPSTF) 
      has initiated a process for systematically reviewing cost-effectiveness analyses 
      as an aid in making recommendations about clinical preventive services. In this 
      paper, we provide an overview and examples of roles for using cost-effectiveness 
      analyses to inform preventive services recommendations, discuss limitations of 
      cost-effectiveness data in shaping evidence-based preventive health care 
      policies, outline the USPSTF approach to using cost-effectiveness analyses, and 
      discuss the methods the USPSTF is developing to assess the quality and results of 
      cost-effectiveness studies. While this paper focuses on clinical preventive 
      services (i.e., screening, counseling, immunizations, and chemoprevention), the 
      framework we have developed should be broadly portable to other health care 
      services.
FAU - Saha, S
AU  - Saha S
AD  - Evidence-Based Practice Center, Oregon Health Sciences University, Portland, 
      Oregon, USA. sahas@ohsu.edu
FAU - Hoerger, T J
AU  - Hoerger TJ
FAU - Pignone, M P
AU  - Pignone MP
FAU - Teutsch, S M
AU  - Teutsch SM
FAU - Helfand, M
AU  - Helfand M
FAU - Mandelblatt, J S
AU  - Mandelblatt JS
CN  - Cost Work Group, Third US Preventive Services Task Force
LA  - eng
GR  - 290-97-0011/PHS HHS/United States
GR  - 290-97-0018/PHS HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Am J Prev Med
JT  - American journal of preventive medicine
JID - 8704773
SB  - IM
MH  - Advisory Committees
MH  - *Cost-Benefit Analysis
MH  - Delivery of Health Care/economics
MH  - Evidence-Based Medicine/*economics
MH  - Humans
MH  - Models, Economic
MH  - Preventive Health Services/*economics
MH  - United States
MH  - United States Agency for Healthcare Research and Quality
EDAT- 2001/04/18 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/04/18 10:00
PHST- 2001/04/18 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/04/18 10:00 [entrez]
AID - S0749379701002604 [pii]
AID - 10.1016/s0749-3797(01)00260-4 [doi]
PST - ppublish
SO  - Am J Prev Med. 2001 Apr;20(3 Suppl):36-43. doi: 10.1016/s0749-3797(01)00260-4.